The week of September 17, 2026 finds the plaintiff personal injury bar managing a confluence of macro forces: a major statutory reform in the nation's second-largest auto-accident jurisdiction, one of the largest mass-tort settlements in history awaiting a final sign-off, and data confirming that the nuclear-verdict era is not receding. Here is what practitioners need to know.
New York Auto Tort Reform: Four Months In, the Inventory Shakeout Is Real
New York's sweeping motor vehicle tort reform package, effective for all actions commenced on or after May 26, 2026, is now shaping intake decisions at plaintiff firms from Buffalo to Brooklyn. The reform eliminated the 90/180-day category of serious injury under Insurance Law 5102(d), the provision that had allowed claims based on temporary impairments lasting at least 90 days within the first 180 days post-accident. Eight categories remain, and the practical effect is that soft-tissue injuries resolving within six months now face a significant threshold barrier.
The reform's other structural changes cut deeper. The state moved from pure comparative fault to a modified rule that bars non-economic damages for plaintiffs found more than 50 percent at fault. A separate provision caps non-economic recovery at $100,000 for certain classes of at-fault defendants: uninsured motorists, impaired drivers, and operators committing a felony at the time of impact. Trial sequencing also changed: juries now determine fault before addressing serious injury, and prejudgment interest does not begin to accrue until findings on both negligence and the serious-injury threshold are entered.
Defense-side commentary from carriers and their coverage counsel has been uniformly enthusiastic about the reforms. Plaintiff bar reactions have been more calibrated. Firms heavy in moderate soft-tissue inventory are already culling files that no longer clear the threshold or whose net value under the modified comparative fault rule drops below the cost of prosecution. Firms with predominantly catastrophic and permanent-injury inventory report minimal disruption because those claims clear the remaining threshold categories (significant limitation of use, permanent consequential limitation, and significant disfigurement) without difficulty.
The reforms also directed a change in trial procedure for the serious-injury threshold issue itself. Courts are now instructed to address threshold in a pre-trial context where the evidence supports it, which mirrors practice in New Jersey and other states with threshold systems. Watch for a wave of early summary judgment motions through the end of 2026 as defendants test which soft-tissue categories are viable under the new rules.
J&J Talc: The $5.5 Billion Settlement and What Comes Next
Johnson & Johnson confirmed in July 2026 that it had reached a framework agreement to settle the talcum powder ovarian cancer litigation for approximately $5.5 billion, resolving claims from roughly 76,000 individuals. The deal followed the collapse of J&J's third bankruptcy-maneuver attempt, and the company has confirmed it will not appeal the bankruptcy ruling that cleared the way for litigation to resume. The settlement is working through the required federal court approval process in MDL 2738 in the District of New Jersey.
For plaintiff firms holding talc inventory, the mechanics of claims administration are now the priority. Individual allocation will depend on each claimant's diagnosis (ovarian cancer vs. mesothelioma), exposure history, and the filing posture of the individual case. Firms that joined the MDL prior to the settlement framework should be auditing their files for completeness of the exposure and medical documentation that allocation administrators will require. Stragglers who filed after the framework was announced may face eligibility questions depending on how the settlement documents define the class.
In parallel state court litigation, Minnesota juries have returned mesothelioma verdicts against talc defendants in the $65 million range during 2026, providing useful settlement leverage for plaintiffs outside the ovarian cancer MDL whose claims involve asbestos-contaminated talc products. The distinction between the ovarian cancer and mesothelioma theories remains legally and scientifically important in terms of causation expert requirements and defendant identification.
Nuclear Verdicts: The 2024 Data, and What It Means for 2026 Trial Planning
Sedgwick's 2025 Liability Litigation Commentary, released earlier this year, quantified what plaintiff practitioners have been experiencing anecdotally: nuclear verdicts (awards exceeding $10 million) rose 52 percent in 2024 compared to the prior year. Verdicts exceeding $100 million surged by 81.5 percent. The average jury verdict across civil cases now exceeds $51 million, a figure that is distorted by the tail of mega-verdicts but that is nonetheless reshaping carrier reserve practices and settlement authority processes.
What the data means operationally for plaintiff firms heading into fall 2026 trial calendars:
- Demand letter recalibration: Pre-suit demand letters anchored to prior settlement ranges in comparable cases are consistently undershooting current verdict potential, particularly in premises and auto cases involving serious permanent injuries. Firms using standard demand templates without updating them to reflect current verdict data are leaving value on the table before litigation even begins.
- Defense behavior at mediation: Carrier representatives and defense firms are presenting authority levels that still reflect pre-nuclear-era settlement expectations. Plaintiff counsel who can put accurate, case-matched nuclear-verdict comparables in front of a mediator early in the process are moving authority in mediation where others are not.
- Voir dire and jury selection: High verdict awards are now a mainstream media story rather than a legal industry specialty topic. Jurors come into courtrooms with pre-formed views about large verdicts that plaintiff counsel need to address during voir dire rather than hoping will resolve themselves.
Florida Premises Verdict: The Park Social Award Survives Post-Trial Motions
An Orange County, Florida jury's award of more than $644 million against the owners and operators of the Park Social bar and entertainment venue in Winter Park has cleared initial post-trial challenge, according to court watchers. The case involved a patron who suffered catastrophic injuries in a fall on the venue's staircase. The verdict is likely headed for appellate review, and Florida's tort reform framework, which imposed new limitations on noneconomic damages and fee arrangements in 2023, will be tested as the case makes its way through the courts. The outcome of that appellate track is one of the more consequential pending premises-liability questions in the Southeast.
Mass Tort Docket Update
Beyond talc, the mass tort docket as of mid-September 2026 carries approximately 206,000 pending MDL cases. The proton-pump inhibitor MDL (MDL 2789 in the Southern District of Florida) continues to add cases as litigation over kidney and cardiovascular injury claims from long-term PPI use progresses through Daubert hearings. The Bair Hugger warming device MDL in Minnesota, now at over 8,400 cases, has bellwether trials proceeding. The 3M Combat Arms Earplug MDL, the largest in history by case count, has moved into a settlement administration phase following the global resolution framework approved earlier this year.
Plaintiff firms managing mass tort inventory heading into Q4 should be auditing their dockets for cases that pre-date expert disclosure deadlines in the relevant MDLs. Missed CMO deadlines are generating dismissals with prejudice in several active MDLs at a pace that should concern firms whose docket management is not keeping up with case management orders.
For weekly coverage of PI practice trends, see industry news. The case-law-settlements section has additional coverage of recent appellate rulings reshaping PI doctrine this quarter.